Redhill Biopharma Ltd. (NASDAQ:RDHL) has received a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $31.50.

A number of equities research analysts recently weighed in on RDHL shares. HC Wainwright set a $33.00 price objective on shares of Redhill Biopharma and gave the company a “buy” rating in a research report on Wednesday, July 26th. Roth Capital set a $27.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research lowered shares of Redhill Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, July 29th. Seaport Global Securities began coverage on shares of Redhill Biopharma in a research note on Friday. They set a “buy” rating for the company. Finally, FBR & Co restated a “buy” rating on shares of Redhill Biopharma in a research report on Friday, June 16th.

A number of institutional investors have recently modified their holdings of RDHL. Renaissance Technologies LLC boosted its holdings in Redhill Biopharma by 144.1% in the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock valued at $595,000 after purchasing an additional 36,600 shares during the period. Jane Street Group LLC bought a new stake in Redhill Biopharma in the 1st quarter valued at $276,000. Family Management Corp bought a new stake in Redhill Biopharma in the 1st quarter valued at $163,000. Bank of New York Mellon Corp bought a new stake in Redhill Biopharma in the 1st quarter valued at $101,000. Finally, Oppenheimer & Co. Inc. boosted its holdings in Redhill Biopharma by 36.5% in the 1st quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 6,172 shares during the period. 10.99% of the stock is owned by hedge funds and other institutional investors.

Shares of Redhill Biopharma (RDHL) opened at 9.90 on Friday. The firm’s market cap is $169.91 million. The firm’s 50-day moving average price is $8.95 and its 200-day moving average price is $9.33. Redhill Biopharma has a 12 month low of $8.16 and a 12 month high of $14.74.

Redhill Biopharma (NASDAQ:RDHL) last issued its quarterly earnings data on Tuesday, July 25th. The biotechnology company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The business had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $0.34 million. Analysts expect that Redhill Biopharma will post ($2.36) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Redhill Biopharma Ltd. (RDHL) Given Average Recommendation of “Buy” by Brokerages” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/06/redhill-biopharma-ltd-rdhl-given-average-recommendation-of-buy-by-brokerages.html.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.